Memantine in dementia: a review of the current evidence (Q37850821)

24 August 2017

1 reference

title

Memantine in dementia: a review of the current evidence (English)

1 reference

24 August 2017

0 references

3

Krista Lanctôt

1 reference

24 August 2017

Nathan Herrmann

1

1 reference

PubMed ID

21385152

24 August 2017

Abby Li

series ordinal

2

1 reference

PubMed ID

21385152

24 August 2017

language of work or name

English

0 references

publication date

9 March 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

1 reference

24 August 2017

12

1 reference

24 August 2017

787-800

1 reference

24 August 2017

5

1 reference

Forecasting the global burden of Alzheimer’s disease

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

The role of glutamate in neurotransmission and in neurologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Excitatory amino acids and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Brain lesions in an infant rhesus monkey treated with monsodium glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Glutamate-induced brain damage in infant primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Glutamate and the glutamate receptor system: a target for drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Dual action of memantine in Alzheimer disease: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Tau phosphorylation in Alzheimer's disease: pathogen or protector?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine in the treatment of senile dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Spotlight on memantine in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Pharmacodynamics of memantine: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine-induced myoclonus and delirium exacerbated by trimethoprim

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine enhances autonomy in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine (Ebixa) in clinical practice - results of an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Long-term course and effectiveness of combination therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Effect of memantine in Alzheimer's disease evaluated by visual-evoked potentials to pattern-reversal, motion-onset, and cognitive stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Cost effectiveness of memantine in Alzheimer's disease in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

A 6-month, open-label study of memantine in patients with frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.558006

10.1517/14656566.2011.558006

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21385152